|
||
| |||||||
|
GENETIX New - fast, flexible and fully integrated system for array-CGH New Milton, Hampshire, UK, 18 April, 2005 - Genetix Ltd has launched a new, fully integrated system for array-based comparative genomic hybridisation (array-CGH). Part of the company’s Cancer Biology Portfolio, the new approach brings together workstations, reagents and consumables for the array-CGH process. Efficient labelling kits, automated clone pickers, flexible arraying platforms and a high resolution scanning instrument allow users the flexibility to work with a fully integrated system. This encompasses the entire process, from genomic DNA labelling, through to the selection and automated picking of bacterial clones, to the preparation, processing and analysis of the CGH arrays. Importantly, the Genetix methodology provides seamless data tracking which can combine library information with array position and signal analysis to ensure high fidelity data output. Array-CGH has emerged as a valuable technique for analysis of the chromosomal rearrangements and DNA copy number aberrations that characterise certain disease states, including many cancers, genetic abnormalities and acquired genetic diseases. Metaphase spread techniques have traditionally been used for this analysis but array-CGH has proven to offer dramatically improved resolution and specificity as well as significantly increased throughput. Further details on the new Cancer Biology Portfolio and the array-CGH system can be found at www.genetix.com
Text ends About GenetixGenetix Limited provides automated systems for cell biology, and proteomic and genomic research. It supplies many leading academic institutions world-wide and major international companies involved in the drug discovery process including GSK, AstraZeneca and Novartis. Genetix made a significant contribution to the Human Genome Project by supplying high-throughput equipment to seven of the leading eight laboratories of the consortium. Genetix, through its R&D expertise and scientific resource, is committed to the continual development of innovative solutions to accelerate the rate of global scientific discovery. Genetix is quoted on the London Stock Exchange (symbol GTX) and is based in New Milton, Hampshire, UK. www.genetix.com A high resolution image is available from Richard Kent at Kapler Communications – richard@kapleronline.com Please quote reference number GEN/PRL/008 Enquiries:Genetix LtdSue Richards PhD, Strategic Business Manager Tel: +44 (0)1425 624 600 Email: sue.richards@genetix.com Media enquiries: Kapler Communications Ltd Richard Kent, Director Tel: +44 (0) 1480 471 117 |
|
| ||||||||
